StockNews.com Upgrades iBio (NYSE:IBIO) to Sell

iBio (NYSE:IBIO) was upgraded by equities researchers at StockNews.com to a “sell” rating in a report released on Tuesday.

iBio Trading Down 2.9 %

Shares of IBIO stock opened at $4.39 on Tuesday. iBio has a 12-month low of $1.05 and a 12-month high of $6.89. The firm has a fifty day moving average of $3.89 and a 200-day moving average of $2.93. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.76 and a quick ratio of 1.76.

Insider Buying and Selling

In other iBio news, Director David Arkowitz purchased 18,382 shares of the firm’s stock in a transaction on Friday, January 10th. The stock was acquired at an average price of $2.72 per share, for a total transaction of $49,999.04. Following the purchase, the director now owns 18,382 shares of the company’s stock, valued at $49,999.04. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.58% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On iBio

An institutional investor recently raised its position in iBio stock. Geode Capital Management LLC raised its holdings in shares of iBio, Inc. (NYSE:IBIO) by 52.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 83,797 shares of the company’s stock after acquiring an additional 28,775 shares during the period. Geode Capital Management LLC owned about 0.85% of iBio worth $205,000 at the end of the most recent reporting period. 7.90% of the stock is currently owned by institutional investors and hedge funds.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.